A non-controlled, single arm, open label, Phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer

Trial Profile

A non-controlled, single arm, open label, Phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2017

At a glance

  • Drugs H 1PV (Primary) ; H 1PV (Primary)
  • Indications Pancreatic cancer
  • Focus Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms ParvOryx02
  • Sponsors Oryx GmbH & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 May 2017 According to an Oryx GmbH & Co media release, topline data from this trial expected in Q4 2017.
    • 26 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top